A real-world study comparing efficacy and safety of the JAK inhibitors tofacitinib and baricitinib in patients with rheumatoid arthritis
Latest Information Update: 02 Sep 2021
Price :
$35 *
At a glance
- Drugs Baricitinib (Primary) ; Tofacitinib (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- 23 Jul 2021 Results comparing the efficacy and safety of tofacitinib and baricitinib in patients with Rheumatoid-arthritis, published in the Arthritis Research and Therapy
- 22 Jun 2021 New trial record
- 05 Jun 2021 Results presented at the 22nd Annual Congress of the European League Against Rheumatism